Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse

Citation
K. Sugano et al., Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse, INT J CANC, 89(4), 2000, pp. 329-336
Citations number
30
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF CANCER
ISSN journal
0020-7136 → ACNP
Volume
89
Issue
4
Year of publication
2000
Pages
329 - 336
Database
ISI
SICI code
0020-7136(20000720)89:4<329:CMOTCP>2.0.ZU;2-3
Abstract
c-erbB-2 protein levels in tissue extracts and sera were determined in a re trospective analysis of 158 patients who underwent surgical resection of br east carcinoma by means of a sandwich enzyme immunometric assay (EIA) using monoclonal antibodies (MAbs) directed to the extracellular domain of the c -erbB-2 oncogene protein (ErbB-2). In the analysis of tissue extracts, 48 s amples (30.3%) showed ErbB-2 levels exceeding 18.0 ng/mg protein (group A), while in 110 samples these levels were below 18.0 ng/mg protein (group B). Immunohistochemical examination of resected tissues using anti-c-erbB-2 an tibody revealed positive staining in 93.8% (45/48) in group A and 13.6%(15/ 110) in group B (p < 0.00001). The proportion of patients who preoperativel y showed a serum ErbB-2 value above 5.4 ng/ml was 52.1% (25/48) in group A and 10.0% (11/110) in group B (p < 0.00001). Thus, the level of ErbB-2 in t issue extracts was significantly associated with immunohistochemistry and E rbB-2 levels in preoperative sera. During follow-up, 48 patients (30.3%) de veloped recurrent disease: 17 in group A (35.4%) and 31 in group B (28.2%). From an ROC analysis based on the postoperative serum ErbB-2 revels in pat ients either with or without relapse, the cutoff value of serum ErbB-2 for tumor relapse was determined to be 6.5 ng/ml. The sensitivity of serum ErbB -2 in patients with relapsed breast cancer was 58.3% (21/36) overall, 84.6% (11/13) in group A and 43.5% (10/23) in group B. In the analysis of serum samples taken before relapse, 90.9% (10/11) of the subjects in group A and 26.7% (4/15) of those in group B were shown to be positive for serum ErbB-2 . Serum ErbB-2 in group A was a more sensitive marker than other tumor mark ers such as CEA, CA15-3, and NCC-ST-439. Thus, the determination of ErbB-2 in tissue extracts of breast carcinoma may be useful for assessing c-erbB-2 protein expression in the primary tissue and indicates that serum ErbB-2 m ay be a sensitive marker for monitoring tumor relapse. (C) 2000 Wiley-Liss, Inc.